Author’s response to reviews

Title: Transglucosidase improves the gut microbiota profile of type 2 diabetes mellitus patients: A randomized double-blind, placebo-controlled study

Authors:

Makoto Sasaki (msasaki@aichi-med-u.ac.jp)
Naotaka Ogasawara (nogasa@aichi-med-u.ac.jp)
Yasushi Funaki (momomaru@aichi-med-u.ac.jp)
Mari Mizuno (mari@aichi-med-u.ac.jp)
Akihito Iida (iida@aichi-med-u.ac.jp)
Chiho Goto (chiho@nagoya-bunri.ac.jp)
Satoshi Koikeda (skoikeda@amano-enzyme.ne.jp)
Kunio Kasugai (kuku3487@aichi-med-u.ac.jp)
Takashi Joh (tjoh@med.nagoya-cu.ac.jp)

Version: 8 Date: 9 April 2013

Author’s response to reviews: see over
To,
The Editor-in-Chief
BMC Gastroenterology
MS: 5703470318684932

April 9, 2013

Dear Editor:

We have enclosed our revised manuscript (5703470318684932) entitled “Transglucosidase improves the gut microbiota profile of type 2 diabetes mellitus patients: A randomized double-blind, placebo-controlled study” by Makoto Sasaki, Naotaka Ogasawara, Yasushi Funaki, Mari Mizuno, Akihito Iida, Chiho Goto, Satoshi Koikeda, Kunio Kasugai, and Takashi Joh.

We hope that you will find our revised manuscript acceptable for publication in BMC Gastroenterology, and that the contents of our paper will be of interest to your journal’s readership.

Thank you for your consideration.

Sincerely,

Makoto Sasaki, M.D., Ph.D.
Department of Gastroenterology,
Aichi Medical University School of Medicine
1-1 Yazakokarimata, Nagakute,
Aichi 480-1195, Japan
Phone: +81-561-62-3311
Fax: +81-561-62-1508
E-mail: msasaki@aichi-med-u.ac.jp
Answer to Comment

Thank you for your help in improving the quality of our manuscript. Firstly, we apologize that the revised manuscript had not uploaded.

1. We described Trial registration number (UMIN000010318) in the abstract.
2. We have revised our manuscript accordingly which was shown in red color sentence in the methods and results section following CONSORT guidelines, and added flow diagram (Figure 1).
3. We have included a power calculation in the revised manuscript as follows (page 7, lines 6–9):
   “The sample size calculation was based on a previous study [2, 6], and based on alpha of 0.05 with a power of 80%. Taking into account a drop-out of 10%, a total sample size of 66 patients will be randomized.”
4. We have included summaries in the discussion section as follows: (page 13, lines 10–13)
   “In summary, we indicated that T2DM in humans is associated with compositional changes in intestinal microbiota, and TGD treatment improved metabolic condition of T2DM and fecal microbiota. These evidence suggests that there is the link between metabolic disease and bacterial population in the gut.”